Ditch Labs Inc. Enters Agreement with Meditrial Europe Ltd to Conduct First Clinical Trial
Ditch Labs Inc. ("Ditch Labs") is pleased to announce that it has entered into an agreement with Meditrial Europe Ltd ("Meditrial") to conduct Ditch Labs' first clinical trial. The trial, which will take place in the Czech Republic, will test the pharmacokinetic, safety, and efficacy of the Ditch system.
The Ditch system consists of a revolutionary device designed to help patients quit smoking, paired to a digital therapeutic application. It has the potential to significantly improve patient outcomes and reduce the negative health effects of smoking. The clinical trial will provide valuable data on the performance of the Ditch system and help determine its potential for widespread use.
"We are very excited to partner with Meditrial for our first clinical trial," said Laurent Laferriere, CEO of Ditch Labs. "This marks an important milestone in our journey, after years of research, product development and preclinical testing. Meditrial is a leading clinical research organization with a strong track record in conducting high-quality clinical trials. We believe this partnership will be instrumental in the successful completion of our trial and the advancement of the Ditch system."
"As Chief Scientific Officer of Ditch Labs, I am particularly enthusiastic about this clinical trial," said Dr. Christelle Luce. “An evidence-based approach is essential to understand the impact of the various components of our treatment on successful smoking cessation, reduction of nicotine withdrawal symptoms, and improvement of quality of life. This randomized controlled trial will provide us with valuable data that will inform future development and the regulatory approval process of the Ditch treatment.”
"We are thrilled to be working with Ditch Labs on this exciting clinical trial," said Dr. Monica Tocchi, Founder and CMO of Meditrial. "The Ditch system has the potential to make a real difference in the lives of patients, and we are committed to helping Ditch Labs bring this innovative product to market."
The clinical trial is expected to begin in the coming months and will enroll a diverse group of adult cigarette smokers. The results of the trial will be used to inform Ditch Labs about its medical device, but also about the pharmacological and psychological aspects of its treatment.
For more information about Ditch Labs and the Ditch system, please click here.
About Ditch Labs Inc.
Ditch Labs is a medical device company dedicated to improving patient outcomes through innovative technologies. The company's flagship product, the DitchPen™, is a revolutionary device designed to help patients quit smoking and reduce the negative health effects of smoking.
About Meditrial Europe Ltd
Meditrial is a leading clinical research organization with a strong track record in conducting high-quality clinical trials. The company has a global network of experienced professionals and state-of-the-art facilities, making it a preferred partner for pharmaceutical and medical device companies seeking to conduct clinical research.